晚期肝细胞癌免疫检查点抑制剂的临床研究进展  

Progress of clinical research on immune checkpoint inhibitorsin advanced hepatocellular carcinoma

作　　者：李代龙 王雨珂 庞雅琪 许新华[1,2] LI Dailong;WANG Yuke;PANG Yaqi;XU Xinhua(The First Clinical Medical College of Three Gorges University,Yichang Central People′s Hospital,Yichang 443003,China;不详)

机构地区：[1]三峡大学第一临床医学院&宜昌市中心人民医院,湖北宜昌443003 [2]三峡大学肿瘤防治中心/三峡大学肿瘤研究所,湖北宜昌443003

出　　处：《实用医学杂志》2021年第6期821-826,共6页The Journal of Practical Medicine

基　　金：湖北省自然科学基金计划项目(编号:2011CDB330,2014CFB312);湖北省卫生和计划生育委员会重大项目(编号:WJ2017Z026)。

摘　　要：肝细胞癌(hepatocellular carcinoma,HCC)作为一种高发病率,高死亡率的恶性肿瘤,早期无明显症状,大多数患者就诊时即为晚期,无法接受根治性手术治疗。以索拉非尼为代表的分子靶向药物是晚期HCC的标准治疗方案,但疗效并不理想。近年来,以免疫检查点抑制剂(immune checkpoint inhibi-tors,ICIs)为代表的免疫治疗在晚期HCC中取得了令人瞩目的成果。本文将对ICIs在晚期HCC中的临床研究现状进行简要综述。Hepatocellular carcinoma(HCC)is a malignant tumor with high morbidity and mortality,which has no obvious symptoms in the early stage.At the time of diagnosis,most patients are already in the advanced stage and cannot receive radical surgery.Molecular targeted drugs represented by sorafenib are the stan⁃dard treatment for advanced HCCbut the efficacy is still not ideal.In recent years,immunotherapy represented by immune checkpoint inhibitors(ICIs)achieved remarkable results in advanced HCC.This article wouldbriefly review the clinical research status of ICIs in advanced HCC.

关 键 词：肝细胞癌 免疫治疗 免疫检查点抑制剂 联合治疗 

分 类 号：R735.7[医药卫生—肿瘤]